<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00497055</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DA022190-01</org_study_id>
    <secondary_id>1R01DA022190-01</secondary_id>
    <secondary_id>1R01DA023387-01</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00497055</nct_id>
  </id_info>
  <brief_title>Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals</brief_title>
  <official_title>Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Francisco Department of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>San Francisco Department of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies demonstrate that methamphetamine (meth) use is associated with high-risk sexual
      behavior among men who have sex with men (MSM), putting meth-using MSM at extraordinarily
      high risk for transmitting or acquiring HIV. This study is a randomized, double-blind,
      placebo-controlled trial of the medication aripiprazole for methamphetamine-using
      individuals, including MSM, and will assess efficacy, acceptability, tolerability, safety,
      and adherence to study medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Population-based surveys estimate that the prevalence of methamphetamine use is 20 times
      higher among men who have sex with men (MSM) compared to the general population.
      Methamphetamine-associated sexual risk behavior is also a driving force in the MSM HIV
      epidemic: methamphetamine use has been associated with increased number of sexual partners,
      unprotected sex acts, sexually transmitted infections (STIs), and HIV acquisition. Despite
      these alarming data, relatively few interventions have been tested among
      methamphetamine-using MSM. Among heterosexual non-injection drug users, methamphetamine use
      has been associated with well characterized risks for HIV and STDs including increased
      numbers of sexual partners, less condom use than non-methamphetamine users, engaging in sex
      work, and self-reported history of STDs. In parallel with the continued testing of behavioral
      approaches, we believe the time has come to test the feasibility and acceptability of
      pharmacologic interventions to reduce methamphetamine use among high-risk individuals.
      Pharmacologic approaches to treating substance use have been successful in treating nicotine,
      alcohol, and heroin dependencies. Preliminary dosing studies demonstrate that aripiprazole
      (Abilify), an FDA-approved, well-tolerated antipsychotic and partial dopamine agonist,
      reduced the effects of methamphetamine in humans and exhibited a good safety profile. We
      propose to expand upon these promising results by conducting a randomized, double-blind,
      placebo-controlled pilot study of aripiprazole among sexually-active,
      methamphetamine-dependent individuals.

      The specific aims of this study are:

        1. To test the hypothesis that aripiprazole 20 mg daily will reduce methamphetamine use
           significantly more than placebo among methamphetamine-dependent individuals, as
           determined by the proportion of methamphetamine-negative urines and by self-report of
           methamphetamine use in the aripiprazole versus placebo group.

        2. To measure the acceptability of aripiprazole and placebo among methamphetamine-dependent
           individuals, by determining (via electronic pill caps and self-report) medication
           adherence to aripiprazole and placebo.

        3. To measure the safety and tolerability of aripiprazole and placebo among
           methamphetamine-dependent individuals, as determined by the number of adverse clinical
           events in the aripiprazole and placebo arms.

      If promising, study results will be used to design larger, definitive clinical trials to
      determine the efficacy of aripiprazole in reducing methamphetamine use and corresponding
      methamphetamine-associated sexual risk among MSM. This pilot study is therefore designed to
      reflect the structure of such trials. We will enroll 90 sexually active,
      methamphetamine-dependent individuals who will be randomized 1:1 to receive aripiprazole
      (n=45) or placebo (n=45) for 12 weeks. Because we are testing a drug for a new indication in
      a new population, we will include extensive safety parameters, as done in prior studies of
      pharmacologic interventions among substance users. We will also include both urine testing
      and extensive behavioral risk assessments because we anticipate that future definitive
      efficacy trials will analyze both substance use and sexual risk behavior outcomes. Study
      participants will be seen at the San Francisco Department of Public Health AIDS Office where
      they will provide urines for drug testing and participate in substance use counseling. All
      participants will receive HIV risk-reduction counseling. Behavior will be assessed using
      standardized measures via audio computer-assisted self-interview (ACASI).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Test the Hypothesis That Aripiprazole 20 mg Daily Will Reduce Methamphetamine Use Significantly More Than Placebo Among Methamphetamine-dependent Individuals.</measure>
    <time_frame>Final study visit at week 12</time_frame>
    <description>To test the hypothesis that aripiprazole 20 mg daily will reduce methamphetamine use significantly more than placebo among methamphetamine-dependent individuals, as determined by the proportion of methamphetamine-positive urines in the aripiprazole versus placebo group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Measure the Acceptability of Aripiprazole and Placebo Among Methamphetamine-dependent Individuals, by Determining (Via Electronic Pill Caps [MEMS or Medication Event Monitoring System]) Medication Adherence to Aripiprazole and Placebo.</measure>
    <time_frame>Adherence as determined by MEMS (throughout study, up to 12 weeks)</time_frame>
    <description>To measure the acceptability of aripiprazole and placebo among methamphetamine-dependent individuals, by determining (via electronic pill caps [MEMS or Medication Event Monitoring System]) medication adherence to aripiprazole and placebo. (Percent adherence from MEMS is determined by 100* the number of days where MEMS registered an opening out of the number of days a dose was prescribed for each arm.)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Measure the Safety and Tolerability of Aripiprazole and Placebo Among Methamphetamine-dependent Individuals, as Determined by the Number of Adverse Clinical Events in the Aripiprazole and Placebo Arms.</measure>
    <time_frame>Total reported adverse events (throughout study, up to 12 weeks)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Substance Abuse</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aripiprazole 5mg daily for week one. Aripiprazole 10mg daily for week two. Aripiprazole 20mg daily for weeks three through twelve.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for Aripiprazole) 5mg daily for week one. Placebo (for Aripiprazole) 10mg daily for week two. Placebo (for Aripiprazole) 20mg daily for weeks three through twelve.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <arm_group_label>Aripiprazole</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill manufactured to mimic Aripiprazole gel caps.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        A total of 90 high-risk individuals with methamphetamine dependence will be enrolled in the
        study. Subjects will be San Francisco Bay Area residents between 18-60 years of age and in
        good health. The project is designed specifically for those at high risk for HIV
        transmission or acquisition.

        Inclusion Criteria:

          1. HIV-negative by rapid test, or documentation of HIV infection with a laboratory result
             of a positive HIV test;

          2. diagnosed with methamphetamine dependence as determined by SCID;

          3. interested in stopping or reducing methamphetamine use;

          4. at least one methamphetamine-positive urine during screening and run-in period;

          5. no current acute illnesses requiring prolonged medical care;

          6. no chronic illnesses that are likely to progress clinically during trial
             participation;

          7. able and willing to provide informed consent and to be followed over trial period;

          8. age 18-60 years;

          9. baseline CBC, total protein, albumin, glucose, lipid panel, alk phos, creatinine, BUN,
             and electrolytes without clinically significant abnormalities as determined by
             investigator in conjunction with symptoms, physical exam, and medical history.

         10. if sex assigned at birth was female and able to become pregnant: agrees to use birth
             control by any of the following methods - hormonal patch, pills, or injections; IUD;
             diaphragm; condoms; or abstinence.

        Exclusion Criteria:

          1. has a psychiatric disorder as assessed by SCID that in the opinion of evaluating
             clinician would make the study participation unsafe, or make adherence to study
             protocol untenable. Conditions include current major depression, current suicidal
             ideation, bipolar disorder, dementia, or acute psychosis;

          2. taking psychotropic medication within the last 30 days, including aripiprazole;

          3. known allergy to aripiprazole, or known adverse reaction to antipsychotics;

          4. currently using or unwilling not to use phenylephrine or ephedrine-containing products
             for trial duration (can cause false positive urines for methamphetamine use);

          5. current CD4 count &lt; 200 cells/mm3;

          6. using other medications known to interact with aripiprazole, including ketoconazole
             and carbamazepine;

          7. measured moderate or severe liver disease (AST, ALT, and total bilirubin &gt; 3 times
             normal) and/or any symptoms of current liver disease;

          8. impaired renal function (creatinine clearance &lt; 60 ml/min);

          9. diabetes mellitis type I or type II, including cases controlled with diet alone;

         10. Hypertension that is not well-controlled;

         11. BMI ≥ 40; or BMI ≥ 35 with more than one of the following: age &gt; 45, systolic blood
             pressure &gt; 140 mm Hg, diastolic blood pressure &gt; 90 mm Hg, known hyperlipidemia;

         12. History of, or known active cardiovascular disease including: (a) Previous myocardial
             infarction (heart attack); (b) angina pectoris; (c) congestive heart failure; (d)
             valvular heart disease including mitral valve prolapse; (e) cardiomyopathy; (f)
             pericarditis; (g) stroke or transient ischemic attack; (h) chest pain or shortness of
             breath with activity (such as walking up stairs); (i) peripheral vascular disease or
             risk equivalent; (j) other heart conditions under the care of a doctor;

         13. currently participating in another research study;

         14. pregnant, breast-feeding, and/or positive pregnancy test at screening or enrollment
             visit;

         15. any condition that, in the principal investigator's judgment, interferes with safe
             study participation or adherence to study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip O Coffin, MD, MIA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Substance Use Research, San Francisco Department of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco Department of Public Health, AIDS Office</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Coffin PO, Santos GM, Das M, Santos DM, Huffaker S, Matheson T, Gasper J, Vittinghoff E, Colfax GN. Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction. 2013 Apr;108(4):751-61. doi: 10.1111/add.12073. Epub 2013 Jan 3.</citation>
    <PMID>23186131</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2007</study_first_submitted>
  <study_first_submitted_qc>July 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2007</study_first_posted>
  <results_first_submitted>December 12, 2012</results_first_submitted>
  <results_first_submitted_qc>February 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 24, 2014</results_first_posted>
  <last_update_submitted>February 5, 2014</last_update_submitted>
  <last_update_submitted_qc>February 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>San Francisco Department of Public Health</investigator_affiliation>
    <investigator_full_name>Phillip Coffin, MD, MIA</investigator_full_name>
    <investigator_title>Director of Substance Use Research</investigator_title>
  </responsible_party>
  <keyword>Methamphetamine</keyword>
  <keyword>HIV</keyword>
  <keyword>MSM</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aripiprazole</title>
          <description>Aripiprazole 5mg daily for week one. Aripiprazole 10mg daily for week two. Aripiprazole 20mg daily for weeks three through twelve.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo (for Aripiprazole) 5mg daily for week one. Placebo (for Aripiprazole) 10mg daily for week two. Placebo (for Aripiprazole) 20mg daily for weeks three through twelve.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aripiprazole</title>
          <description>aripiprazole daily for 3 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo daily for 3 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.4" spread="12.3"/>
                    <measurement group_id="B2" value="40" spread="8.9"/>
                    <measurement group_id="B3" value="38.7" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Test the Hypothesis That Aripiprazole 20 mg Daily Will Reduce Methamphetamine Use Significantly More Than Placebo Among Methamphetamine-dependent Individuals.</title>
        <description>To test the hypothesis that aripiprazole 20 mg daily will reduce methamphetamine use significantly more than placebo among methamphetamine-dependent individuals, as determined by the proportion of methamphetamine-positive urines in the aripiprazole versus placebo group.</description>
        <time_frame>Final study visit at week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>aripiprazole daily for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>To Test the Hypothesis That Aripiprazole 20 mg Daily Will Reduce Methamphetamine Use Significantly More Than Placebo Among Methamphetamine-dependent Individuals.</title>
          <description>To test the hypothesis that aripiprazole 20 mg daily will reduce methamphetamine use significantly more than placebo among methamphetamine-dependent individuals, as determined by the proportion of methamphetamine-positive urines in the aripiprazole versus placebo group.</description>
          <units>perc of positive urines at final visit</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.41</p_value>
            <method>Generalized estimating equation</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>.66</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Measure the Acceptability of Aripiprazole and Placebo Among Methamphetamine-dependent Individuals, by Determining (Via Electronic Pill Caps [MEMS or Medication Event Monitoring System]) Medication Adherence to Aripiprazole and Placebo.</title>
        <description>To measure the acceptability of aripiprazole and placebo among methamphetamine-dependent individuals, by determining (via electronic pill caps [MEMS or Medication Event Monitoring System]) medication adherence to aripiprazole and placebo. (Percent adherence from MEMS is determined by 100* the number of days where MEMS registered an opening out of the number of days a dose was prescribed for each arm.)</description>
        <time_frame>Adherence as determined by MEMS (throughout study, up to 12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>aripiprazole daily for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>To Measure the Acceptability of Aripiprazole and Placebo Among Methamphetamine-dependent Individuals, by Determining (Via Electronic Pill Caps [MEMS or Medication Event Monitoring System]) Medication Adherence to Aripiprazole and Placebo.</title>
          <description>To measure the acceptability of aripiprazole and placebo among methamphetamine-dependent individuals, by determining (via electronic pill caps [MEMS or Medication Event Monitoring System]) medication adherence to aripiprazole and placebo. (Percent adherence from MEMS is determined by 100* the number of days where MEMS registered an opening out of the number of days a dose was prescribed for each arm.)</description>
          <units>percent adherence from MEMS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" spread="32"/>
                    <measurement group_id="O2" value="39" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Measure the Safety and Tolerability of Aripiprazole and Placebo Among Methamphetamine-dependent Individuals, as Determined by the Number of Adverse Clinical Events in the Aripiprazole and Placebo Arms.</title>
        <time_frame>Total reported adverse events (throughout study, up to 12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>aripiprazole daily for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>To Measure the Safety and Tolerability of Aripiprazole and Placebo Among Methamphetamine-dependent Individuals, as Determined by the Number of Adverse Clinical Events in the Aripiprazole and Placebo Arms.</title>
          <units>total reported adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;=0.99</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aripiprazole</title>
          <description>aripiprazole daily for 3 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo daily for 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>metastatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>subdural hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Viral Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Increased Alanine Transaminase (ALT)</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Increased Aspartate Transaminase (AST)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Skin and soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sleep Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed Mood</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection (UTI)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection (URI)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abrasions</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Phillip O. Coffin, Director of Substance Use Research</name_or_title>
      <organization>San Francisco Department of Public Health</organization>
      <phone>415-437-6282</phone>
      <email>phillip.coffin@sfdph.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

